M J Casanova, M Chaparro, E Domènech, M Barreiro-de Acosta, F Bermejo, E Iglesias, F Gomollón, L Rodrigo, X Calvet, M Esteve, E García-Planella, S García-López, C Taxonera, M Calvo, M López, D Ginard, M Gómez-García, E Garrido, J L Pérez-Calle, B Beltrán, M Piqueras, C Saro, B Botella, C Dueñas, A Ponferrada, M Mañosa, V García-Sánchez, J Maté, J P Gisbert
OBJECTIVES: The safety of thiopurines and anti-tumor necrosis factor-α (TNF-α) drugs during pregnancy remains controversial, as the experience with these drugs in this situation is limited. Our aim is to assess the safety of thiopurines and anti-TNF-α drugs for the treatment of inflammatory bowel disease (IBD) during pregnancy. METHODS: Retrospective, multicenter study in IBD patients. Pregnancies were classified according to the therapeutic regimens during pregnancy or during the 3 months before the conception: non-exposed group, pregnancies exposed to thiopurines alone (group A), and pregnancies exposed to anti-TNF-α drugs (group B)...
March 2013: American Journal of Gastroenterology